{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:03:40Z","timestamp":1759147420277,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00811-0","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T09:16:47Z","timestamp":1754990207000},"page":"2095-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment"],"prefix":"10.1007","volume":"14","author":[{"given":"Clara Helena","family":"L\u00f3pez-Caneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ant\u00f3n-Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"P\u00e9rez-Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar Manuel","family":"S\u00e1nchez-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Alvarez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aguado-Valcarcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Marcos-Bobillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Torrente-Carballido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-0771","authenticated-orcid":false,"given":"Ines","family":"Gonz\u00e1lez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"12","key":"811_CR1","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380\u201390.","journal-title":"Am J Med"},{"issue":"3","key":"811_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2014;13(3):247\u201356.","journal-title":"Lancet Neurol"},{"issue":"6","key":"811_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase\u00a03 trial. Mult Scler. 2014;20(6):705\u201316.","journal-title":"Mult Scler"},{"issue":"9","key":"811_CR4","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00415-014-7412-x","volume":"261","author":"DL Arnold","year":"2014","unstructured":"Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase\u00a03 define study. J Neurol. 2014;261(9):1794\u2013802.","journal-title":"J Neurol"},{"issue":"11","key":"811_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1212\/WNL.0000000000001360","volume":"84","author":"DH Miller","year":"2015","unstructured":"Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase\u00a03 CONFIRM study. Neurology. 2015;84(11):1145\u201352.","journal-title":"Neurology"},{"key":"811_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418796404","author":"E D\u2019Amico","year":"2018","unstructured":"D\u2019Amico E, Zangh\u00ec A, Callari G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-world multicenter experience. Ther Adv Neurol Disord. 2018. https:\/\/doi.org\/10.1177\/1756286418796404.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"811_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"17","key":"811_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2217\/cer-2020-0149","volume":"9","author":"F Porzsolt","year":"2020","unstructured":"Porzsolt F, Wiedemann F, Phlippen M, et al. The terminology conflict on efficacy and effectiveness in healthcare. J Comp Eff Res. 2020;9(17):1171\u20138.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"811_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1515\/jcim-2023-0179","volume":"21","author":"F Porzsolt","year":"2023","unstructured":"Porzsolt F. Comparative effectiveness is the common denominator in health services research: experimental effects are promising, real-world effects are compelling. J Complement Integr Med. 2023;21(1):19\u201325.","journal-title":"J Complement Integr Med"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329\u201333.","journal-title":"Mult Scler Relat Disord"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdova E. \u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23:1179\u201387.","journal-title":"Mult Scler"},{"issue":"2","key":"811_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537.","journal-title":"JAMA Neurol"},{"issue":"6","key":"811_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","volume":"12","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]. Neurol Ther. 2023;12(6):1909\u201335.","journal-title":"Neurol Ther"},{"issue":"4","key":"811_CR14","first-page":"718","volume":"23","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Cutter G, Spelman T, et al. Persistence on therapy and adherence to treatment in patients with relapsing-remitting multiple sclerosis from the MSBase registry. Mult Scler. 2017;23(4):718\u201330.","journal-title":"Mult Scler"},{"key":"811_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211019574","author":"T Ziemssen","year":"2021","unstructured":"Ziemssen T, Hoffmann F, Apfel R, et al. Persistence and adherence to immunomodulatory drugs in multiple sclerosis: a retrospective cohort study based on the German NeuroTransData MS Registry. Ther Adv Neurol Disord. 2021. https:\/\/doi.org\/10.1177\/17562864211019574.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"811_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s13311-020-01001-6","volume":"18","author":"E D'Amico","year":"2021","unstructured":"D\u2019Amico E, Zangh\u00ec A, Romeo M, et al. Injectable versus oral first-line disease-modifying therapies: results from the Italian MS register. Neurotherapeutics. 2021;18(2):905\u201319.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"811_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ane.13301","volume":"142","author":"S Lahdenper\u00e4","year":"2020","unstructured":"Lahdenper\u00e4 S, Soilu-H\u00e4nninen M, Kuusisto HM, et al. Medication adherence\/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand. 2020;142(6):605\u201312.","journal-title":"Acta Neurol Scand"},{"key":"811_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102521","volume":"46","author":"P Vermersch","year":"2020","unstructured":"Vermersch P, Suchet L, Colamarino R, Laurendeau C, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014\u20132017. Mult Scler Relat Disord. 2020;46: 102521.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"811_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","volume":"265","author":"R Lanzillo","year":"2018","unstructured":"Lanzillo R, Prosperini L, Gasperini C, et al. A multicentRE observational an\u00e1lisis of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol. 2018;265(5):1174\u201383.","journal-title":"J Neurol"},{"key":"811_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104909","volume":"78","author":"C L\u00f3pez-Caneda","year":"2023","unstructured":"L\u00f3pez-Caneda C, P\u00e9rez-Haro MJ, S\u00e1nchez-Franco C, et al. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2023;78:104909.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"811_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/13524585211019649","volume":"28","author":"J Hillert","year":"2022","unstructured":"Hillert J, Tsai JA, Nouhi M, Glaser A, Spelman T. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS registry. Mult Scler. 2022;28(2):237\u201346.","journal-title":"Mult Scler"},{"issue":"4","key":"811_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","volume":"11","author":"L Araujo","year":"2022","unstructured":"Araujo L, Geertsen SS, Amedume A, et al. Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735\u201348.","journal-title":"Neurol Ther"},{"issue":"7","key":"811_CR23","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","volume":"93","author":"D-A Laplaud","year":"2019","unstructured":"Laplaud D-A, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93(7):e635\u201346.","journal-title":"Neurology"},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"6679197","DOI":"10.1155\/2021\/6679197","volume":"2021","author":"N Nehzat","year":"2021","unstructured":"Nehzat N, Mirmosayyeb O, Barzegar M, et al. Comparable efficacy and safety of teriflunomide versus dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis. Neurol Res Int. 2021;2021:6679197.","journal-title":"Neurol Res Int"},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.msard.2022.103489","volume":"58","author":"A Zangh\u00ec","year":"2022","unstructured":"Zangh\u00ec A, Avolio C, Amato MP, et al. Real world comparison of teriflunomide and dimethyl fumarate in na\u00efve relapsing multiple sclerosis patients: evidence from the Italian MS register. Mult Scler Relat Disord. 2022;58:103489.","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"811_CR26","doi-asserted-by":"publisher","first-page":"e1811","DOI":"10.1212\/WNL.0000000000007314","volume":"92","author":"MD Buron","year":"2019","unstructured":"Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology. 2019;92(16):e1811\u201320.","journal-title":"Neurology"},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","volume":"27","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101\u201311.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"811_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/ene.13839","volume":"26","author":"S Cond\u00e9","year":"2019","unstructured":"Cond\u00e9 S, Moisset X, Pereira B, et al. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol. 2019;26(3):460\u20137.","journal-title":"Eur J Neurol"},{"issue":"10","key":"811_CR29","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1007\/s00415-020-09959-1","volume":"267","author":"E D'Amico","year":"2020","unstructured":"D\u2019Amico E, Zangh\u00ec A, Sciandra M, et al. Dimethyl fumarate vs teriflunomide: an Italian time-to-event data analysis. J Neurol. 2020;267(10):3008\u201320.","journal-title":"J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00811-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:08Z","timestamp":1758367328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00811-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00811-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clara Helena L\u00f3pez-Caneda, Sergio Ant\u00f3n-Fuente, Maria Jos\u00e9 P\u00e9rez-Haro, Cesar Manuel S\u00e1nchez-Franco, Elena Alvarez-Rodr\u00edguez, Marta Aguado-Valcarcel, Maria Marcos-Bobillo, Marta Torrente-Carballido, and Ines Gonz\u00e1lez-Su\u00e1rez have nothing to disclose. Clara Lopez Caneda has changed affiliation. Her current affiliation is the Department of Neurology, Hospital Universitario de Pontevedra, Complexo Hospitalario Universitario de Pontevedra (CHUP), Pontevedra, Galicia, Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the local Ethics Committee of Galicia (approval code 2023\u2013018) and was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments. All participants provided informed consent to participate in the study and for publication of the anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}